Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma

Jacobsen, Audrey A.; Kydd, Andre R.; Strasswimmer, John

doi:10.1016/j.jaad.2016.04.063

Cited by 12 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six months later, the patient was tolerating ongoing vismodegib therapy with only dysgeusia. This is consistent with other reports of the long‐term tolerability of this treatment . Currently, he has reported no other relevant adverse effects.…”

supporting

confidence: 91%

Rapid development of atypical fibroxanthoma during vismodegib treatment

et al. 2018

View full text Add to dashboard Cite

supporting

confidence: 91%

Rapid development of atypical fibroxanthoma during vismodegib treatment

et al. 2018

View full text Add to dashboard Cite

“…These adverse events do have sufficient approaches to management. Strategies for managing dysgeusia, decreased appetite, and weight loss include nutritional consultation and changes in preparation of foods (90,91). Furthermore, there are medicinal options as well that range from fish oil supplementation to corticosteroids (92).…”

Section: 24mentioning

confidence: 99%

Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer

Carpenter

Ray

2019

Drug Saf

View full text Add to dashboard Cite

The hedgehog pathway, for which sonic hedgehog (Shh) is the most prominent ligand, is highly conserved and is tightly associated with embryonic development in a number of species. This pathway is also tightly associated with development of several types of cancer, including basal cell carcinoma and acute promyelocytic leukemia (APL) among many others. Inactivating mutations in Patched 1 (PTCH1), leading to ligand-independent pathway activation, are frequent in several cancer types but most prominent in basal cell carcinoma. This has led to the development of several compounds targeting this pathway as a cancer therapeutic. These compounds target the inducers of this pathway in Smoothened (SMO) and the GLI transcription factors, although targeting SMO has had the most success. Despite the many attempts at targeting this pathway, there are only three FDA-approved drugs for cancers that affect the Shh pathway. Two of these compounds, vismodegib and sonidegib, target SMO to suppress signaling from either PTCH1 or SMO mutations that lead to upregulation of the pathway. The other approved compound is arsenic trioxide (ATO), which can suppress this pathway at the level of the GLI proteins, although current evidence suggests it also has other targets. This review focuses on the efficacy and safety of these clinically-approved drugs targeting the Shh pathway along with a discussion on other Shh pathway inhibitors being developed.

show abstract

“…At the same time, non-BCC damage should also be given comprehensive treatment because synchronous occult amelanotic melanoma has been reported in 25% (3/12) of BCC patients ( Simone et al, 2016 ; Zhu et al, 2014 ). Two BCC patients, five years after Hh signaling pathway inhibitor treatment, have survived by paying close attention to and interfering with various side effects ( Jacobsen et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

树鼩(Tupaia belangeri chinensis)基底细胞癌模型的建立

蒋丽萍¹,

Jiang²,

申秋硕³

et al. 2017

Zool. Res.

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common skin cancer worldwide, with incidence rates continuing to increase. Ultraviolet radiation is the major environmental risk factor and dysregulation of the Hedgehog (Hh) signaling pathway has been identified in most BCCs. The treatment of locally advanced and metastatic BBCs is still a challenge and requires a better animal model than the widely used rodents for drug development and testing. Chinese tree shrews (Tupaia belangeri chinensis) are closely related to primates, bearing many physiological and biochemical advantages over rodents for characterizing human diseases. Here, we successfully established a Chinese tree shrew BCC model by infecting tail skins with lentiviral SmoA1, an active form of Smoothened (Smo) used to constitutively activate the Hh signaling pathway. The pathological characteristics were verified by immunohistochemical analysis. Interestingly, BCC progress was greatly enhanced by the combined usage of lentiviral SmoA1 and shRNA targeting Chinese tree shrew p53. This work provides a useful animal model for further BCC studies and future drug discoveries.

show abstract

Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma

Cited by 12 publications

References 5 publications

Rapid development of atypical fibroxanthoma during vismodegib treatment

Rapid development of atypical fibroxanthoma during vismodegib treatment

Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer

树鼩(Tupaia belangeri chinensis)基底细胞癌模型的建立

Contact Info

Product

Resources

About